Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1/2 1

Status

Active not recruiting 3Recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 5Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Multiple Myeloma 5Leukemia, Hairy Cell 3Burkitt Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Non-Hodgkin 2Hodgkin Disease 2Carcinoma in Situ 2Breast Neoplasms 2Vulvar Neoplasms 1Vulvar Diseases 1Vomiting 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Sarcoma, Alveolar Soft Part 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Postoperative Nausea and Vomiting 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Papillomavirus Infections 1Oropharyngeal Neoplasms 1Neoplasms 1Neoplasm, Residual 1NSCLC 1Myelodysplastic Syndromes 1Mastocytosis, Systemic 1Lymphoma, Follicular 1Lymphoma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

Dexamethasone 242Lenalidomide 147daratumumab 125Bortezomib 102pomalidomide 88Calcium Dobesilate 76carfilzomib 75Cyclophosphamide 71Specimen Handling 42isatuximab 41Biopsy 40belantamab mafodotin 37fludarabine 36Magnetic Resonance Spectroscopy 35talquetamab 29Melphalan 28dexamethasone acetate 27dexamethasone 21-phosphate 27auricularum 26iberdomide 25ixazomib 22fludarabine phosphate 22selinexor 21elotuzumab 21Whole-Body Irradiation 14X-Rays 13tocilizumab 12venetoclax 11Mycophenolic Acid 10trametinib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Multiple Myeloma × Diphenhydramine × 1 year × Clear all
NCT04268498 2026-03-24

ADVANCE

University of Miami

Phase 2 Active not recruiting
310 enrolled
Plasma cell

Multiple Myeloma

NCT05896228 2026-03-11

Iber-KDd

University of Miami

Phase 2 Recruiting
30 enrolled
Plasma cell

Multiple Myeloma

NCT05704049 2025-12-29

IZALCO

Sanofi

Phase 2 Active not recruiting
118 enrolled
Plasma cell

Multiple Myeloma

NCT04270409 2025-12-12

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

Sanofi

Phase 3 Active not recruiting
337 enrolled
Plasma cell

Multiple Myeloma

NCT02356159 2025-09-30

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
34 enrolled 18 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡